Krilogy Financial LLC Has $1.24 Million Position in Medpace Holdings, Inc. $MEDP

Krilogy Financial LLC cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 39.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,398 shares of the company’s stock after selling 1,571 shares during the quarter. Krilogy Financial LLC’s holdings in Medpace were worth $1,237,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in MEDP. Campbell Newman Asset Management Inc. increased its stake in shares of Medpace by 1.6% in the first quarter. Campbell Newman Asset Management Inc. now owns 9,188 shares of the company’s stock valued at $4,412,000 after buying an additional 149 shares during the period. Balboa Wealth Partners boosted its position in Medpace by 37.5% during the 1st quarter. Balboa Wealth Partners now owns 825 shares of the company’s stock worth $396,000 after buying an additional 225 shares during the period. BI Asset Management Fondsmaeglerselskab A S grew its holdings in Medpace by 247.1% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 51,598 shares of the company’s stock worth $24,777,000 after acquiring an additional 36,731 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Medpace in the 4th quarter valued at approximately $2,164,000. Finally, Corient Private Wealth LLC increased its position in Medpace by 7.0% in the 4th quarter. Corient Private Wealth LLC now owns 1,830 shares of the company’s stock valued at $1,029,000 after acquiring an additional 120 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent research reports. Royal Bank Of Canada cut their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Finally, Robert W. Baird reduced their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $519.96 on Friday. The company has a market capitalization of $14.85 billion, a P/E ratio of 32.68, a price-to-earnings-growth ratio of 2.60 and a beta of 1.18. Medpace Holdings, Inc. has a 52-week low of $305.69 and a 52-week high of $628.92. The company’s 50 day moving average price is $451.02 and its 200-day moving average price is $496.81.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period in the prior year, the firm posted $3.67 EPS. The company’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.